Can a new drug combo tame resistant prostate cancer?

NCT ID NCT07745361

Recruiting now Disease control Sponsor: Monte Rosa Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether an investigational oral drug called MRT-2359, when combined with the standard prostate cancer drug apalutamide, can lower PSA levels in men with castration-resistant prostate cancer. The study includes about 25 adults with a specific genetic mutation in the androgen receptor. The main goal is to see if the combination reduces PSA, while also checking safety and other signs of anti-tumor activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRT-2359 (an investigational oral drug) combined with apalutamide (an approved prostate cancer drug)
What this could lead to: If successful, this combination could offer a new treatment option for men with castration-resistant prostate cancer, potentially slowing disease progression and lowering PSA levels.
What could go wrong: This is an early-phase, small trial (25 participants). The combination may not work as hoped, and side effects are possible. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PROSTATE CANCER PROSTATE CANCER (ADENOCARCINOMA)

Contacts and locations

Locations

Henry Ford
NOT_YET_RECRUITING

Novi, Michigan, 48377, United States
Hoag Memorial Hospital Presbyterian
NOT_YET_RECRUITING

Newport Beach, California, 92663, United States
Kansas University Cancer Center
NOT_YET_RECRUITING

Kansas City, Kansas, 66160, United States
Lancaster Urology
NOT_YET_RECRUITING

Lancaster, Pennsylvania, 17601, United States
Levine Cancer Institute
NOT_YET_RECRUITING

Charlotte, North Carolina, 28204, United States
Rocky Mountain Cancer Center
NOT_YET_RECRUITING

Colorado Springs, Colorado, 80907, United States
START Los Angeles
RECRUITING

Los Angeles, California, 90025, United States
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
START New Jersey
RECRUITING

East Brunswick, New Jersey, 08816, United States
Sarah Cannon Research Institute
NOT_YET_RECRUITING

Nashville, Tennessee, 37203, United States
University of Maryland Greenebaum Cancer Center
NOT_YET_RECRUITING

Baltimore, Maryland, 21201, United States
University of Washington Medical Center
NOT_YET_RECRUITING

Seattle, Washington, 98195, United States
Virginia Cancer Specialists
NOT_YET_RECRUITING

Fairfax, Virginia, 22031, United States
XCancer Omaha
NOT_YET_RECRUITING

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.